Why Government Health Programs Overpay for Drugs by 50 Percent

In this episode of The Fiscal Policy Podcast, Lucas and Luna take aim at a costly inefficiency in government spending: prescription drug pricing in public health programs like Medicaid and Medicare Part D. They zero in on a 2025 federal report revealing that government health plans pay on average 50 percent more than the Veterans Health Administration for the same brand-name drugs. They walk through how the VHA's statutory direct-negotiation authority drives prices down, while Medicaid's 'best price' rule and Medicare's non-interference clause lock in higher costs. They also examine why pharmacy benefit managers (PBMs) exacerbate the problem through opaque rebate structures, and why bipartisan legislative attempts to close the gap have stalled. Finally, they consider whether the Inflation Reduction Act's Medicare price negotiation provision—set to affect 10 drugs by 2026—will actually move the needle. A focused look at how procurement rules, not partisanship, drive the biggest waste in federal health spending. #PrescriptionDrugPricing #GovernmentSpending #Medicaid #MedicarePartD #VeteransHealthAdministration #PharmacyBenefitManagers #InflationReductionAct #DrugNegotiation #FiscalPolicy #PublicHealth #Economics #Podcast #FexingoBusiness #BusinessPodcast #GovernmentEfficiency #HealthcareCosts #DrugRebates #Procurement Keep every episode free: buymeacoffee.com/fexingo